What is the connection between GLP-1s and their potential for reducing dementia and Alzheimer’s risk? w/Dr. Jon Durrani

What do you know about Ozempic or Mounjaro? What is the intention behind these GLP-1 drugs? Can they be critical in reducing risks for dementia and Alzheimer’s? Dr. Jon Durrani, a board-certified neurologist, clinical trial investigator, and Chief of Neurology for two regional hospitals, and now the author of his latest book, “The Ultimate Doctor’s Guide to GLP-1’s: Everything You Need to Know”, joins me as a guest on my show. Jon and I go all the way back when we were friends in high school (which was a LONG time ago) and we reunited through this interview for the first time in many years. We dive into topics such as digital detox, cardiovascular health, and other future health issues facing millennials. Check out this episode and learn more about Dr. Durrani’s research. Bio: Dr. Jon Durrani is a board-certified neurologist, clinical trial investigator, and Chief of Neurology at two regional hospitals. With over a decade of experience treating tens of thousands of complex neurological patients, he is an active medical educator and author dedicated to demystifying brain health. Dr. Durrani is a leading clinical voice on metabolic neurology, viewing GLP-1 therapies not merely as weight-loss tools, but as the foundational future of systemic health and long-term neuroprotection. Link to book: Purchase Here